BioAge Labs, Inc.
NASDAQBIOA enters August as one of the week's most dramatic single-stock stories — down 58% in five sessions and 64% in a single day, a collapse that rewrites the entire investment thesis around its lead drug BGE-102. The scale of the move demands a catalyst read first. The stock had been a momentum darling: a prior note recorded an extraordinary relative-strength score and analyst…
Snapshot as of 13 Aug 2026
BIOA enters August as one of the week's most dramatic single-stock stories — down 58% in five sessions and 64% in a single day, a collapse that rewrites the entire investment thesis around its lead drug BGE-102. The…
BioAge Labs heads into its June 10 Q1 follow-up with a widening gulf between a bullish analyst consensus and a stock that has lost ground every timeframe from one day to one month. The Street has not been shy about…
BioAge Labs heads into its Q1 earnings today with options traders firmly positioned on the bullish side — an unusually clean read for a small-cap biotech. The clearest signal is the put/call ratio. At 0.36, it is…
BioAge Labs enters its May 14 Q2 earnings call with a fresh analyst initiation, a strong Q1 beat in the bank, and options traders signalling more confidence than they've shown in months. The timing of Wednesday's BTIG…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for BIOA — free to start on ORTEX.
Sign up for free →Open BIOA on ORTEX